B2BROKER
8.2.2024 09:28:35 CET | Business Wire | Press release
B2Broker, a global powerhouse of liquidity and technology in the B2B sector for crypto, Forex and financial sectors, has partnered with Tools for Brokers (TFB), which provides elite solutions to brokers, liquidity providers, prop trading agencies and hedge funds.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240208106794/en/
B2Broker partners with Tools for Brokers to integrate Trade Processor liquidity bridge into its existing ecosystem, enhancing the flexibility and efficiency of liquidity services it provides. (Graphic: Business Wire)
B2Broker aims to integrate TFB’s Trade Processor liquidity bridge into its existing ecosystem, enhancing the flexibility and efficiency of liquidity services it provides.
Importance of B2Broker and TFB Partnership
This collaboration combines B2Broker’s robust liquidity services with TFB’s cutting-edge Trade Processor technology. Here’s what you can expect from the partnership:
Enhanced Risk Mitigation - Trade Processor liquidity gateway introduces the trade routing feature that significantly elevates risk management capabilities for B2Broker clients. The platform can also provide advanced trade routing solutions to retail brokers with their MT4/MT5 servers. Traders can also seamlessly switch between A-Book and B-Book, increasing their flexibility and ability to adapt to market trends.
Elevated Access - With this integration, B2Broker clients will seamlessly access MT4, MT5 and cTrader platforms. The external FIX API integration is also possible for connecting third-party platforms.
Intuitive UI and Advanced Analytics - the Trade Processor also streamlines the digital user interface, making it easy to obtain essential data and access B2Broker’s features. The trading History page now overviews closed positions and all relevant details. Additional pages allow clients to analyse open position stats and exposure metrics and monitor the server performance.
Arthur Azizov, CEO of B2Broker, shared his thoughts on the partnership: "Our collaboration with Tools for Brokers directly supports our goal to deliver innovative technology to clients. TFB's Trade Processor upgrades our offerings with improved risk management and seamless integration across major trading platforms. At the same time, this partnership opens up B2Broker's extensive liquidity pool of over 800 pairs across eight asset classes to TFB users. It’s a mutual exchange of strengths that promises to enhance the value we, B2Broker and TFB, aim to deliver to our clients."
Alexey Kutsenko, the CEO at Tools for Brokers, outlined his excitement for the upcoming collaboration: “We are excited to partner with B2Broker. The company is well-known for its powerful ecosystem of products for brokers. I am confident that together we will create an even stronger solution for B2Brokers’ clients and help them grow faster and stay resilient.”
About Tools for Brokers
Tools for Brokers (TFB) is a global tech provider that serves retail brokers, LPs, prop trading firms and hedge funds operating on multiple platforms like MT4, MT5, Match-Trader and cTrader. TFB’s solutions are powered by their cutting-edge Trade Processor liquidity bridge. The core technology is further elevated by data analytics, risk mitigation tools, money management solutions and a single digital hub to manage TFB plugins effortlessly.
For more information, visit www.t4b.com
B2Broker’s Services
B2Broker is a global leader in the liquidity and fintech sector. B2Broker provides B2B services to forex brokers, crypto exchange platforms, prop traders, crypto spot brokers, multi-asset brokers and many other industries. B2Broker offers over 800 liquidity instruments supported by eight different asset classes. Moreover, the platform features payment processing solutions, white-label solutions, back-office, and numerous other mechanisms to create a full-stop liquidity and business management service for their B2B clients.
For more information, visit b2broker.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240208106794/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom